These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32178544)

  • 1. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 2. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
    McMahan ZH; Volkmann ER
    Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
    Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
    White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
    Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advances in the treatment of systemic sclerosis.
    Bukiri H; Volkmann ER
    Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
    Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
    Campochiaro C; Allanore Y
    Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review.
    Fernández-Lázaro D; Iglesias-Lázaro M; Garrosa E; Rodríguez-García S; Jerves Donoso D; Gutiérrez-Abejón E; Jorge-Finnigan C
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel investigational agents for the treatment of scleroderma.
    McMahan ZH; Wigley FM
    Expert Opin Investig Drugs; 2014 Feb; 23(2):183-98. PubMed ID: 24261610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs for the treatment of scleroderma: what's new?
    Colic J; Campochiaro C; Hughes M; Matucci Cerinic M; Dagna L
    Expert Opin Investig Drugs; 2023; 32(7):601-614. PubMed ID: 37526079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
    Distler O; Volkmann ER; Hoffmann-Vold AM; Maher TM
    Expert Rev Clin Immunol; 2019 Oct; 15(10):1009-1017. PubMed ID: 31566449
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Costimulatory Pathways in Systemic Sclerosis.
    Boleto G; Allanore Y; Avouac J
    Front Immunol; 2018; 9():2998. PubMed ID: 30619351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
    Khanna D; Brown KK; Clements PJ; Elashoff R; Furst DE; Goldin J; Seibold JR; Silver RM; Tashkin DP; Wells AU
    Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S55-62. PubMed ID: 20576216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
    Fathi N; Furst DE; Clements PJ
    Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.